Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.5 - $31.51 $435,081 - $537,623
17,062 New
17,062 $488,000
Q2 2022

Aug 15, 2022

BUY
$51.49 - $81.64 $15 Million - $23.8 Million
292,000 New
292,000 $17 Million
Q1 2022

May 16, 2022

SELL
$60.03 - $76.49 $35.8 Million - $45.6 Million
-596,338 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$47.97 - $62.21 $17.8 Million - $23.1 Million
-370,898 Reduced 38.35%
596,338 $35.9 Million
Q3 2021

Nov 15, 2021

SELL
$54.64 - $61.3 $9.82 Million - $11 Million
-179,764 Reduced 15.67%
967,236 $54.2 Million
Q2 2021

Aug 16, 2021

SELL
$59.18 - $69.99 $1.06 Million - $1.26 Million
-17,973 Reduced 1.54%
1,147,000 $69.6 Million
Q1 2021

May 17, 2021

BUY
$59.31 - $78.82 $6.84 Million - $9.09 Million
115,326 Added 10.99%
1,164,973 $81.7 Million
Q4 2020

Feb 16, 2021

SELL
$50.47 - $66.26 $7.48 Million - $9.82 Million
-148,178 Reduced 12.37%
1,049,647 $62.8 Million
Q3 2020

Nov 16, 2020

SELL
$51.97 - $63.0 $24.2 Million - $29.3 Million
-465,175 Reduced 27.97%
1,197,825 $72 Million
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $1.09 Million - $1.86 Million
35,479 Added 2.18%
1,663,000 $87.3 Million
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $46.2 Million - $82.5 Million
1,627,521 New
1,627,521 $54.6 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.